However, in research on the Chi-CHOEP regimen, patients with AITL showed significantly inferior outcomes with an mPFS of 9.6 months, compared to anaplastic lymphoma kinase-negative anaplastic large cell lymphoma (ALK−ALCL) (26.0 months) and PTCL-NOS (19.4 months) [94]. This evidence concerns the gene ALK and mature T-cell and NK-cell non-Hodgkin lymphoma.